Author/Editor		Smrdel, Uroš; Kovač, Viljem
Title		Erlotinib in previously treated non-small-cell lung cancer
Translated title		Erlotinib pri zdravljenju nedrobnoceličnega raka pljuč
Type		članek
Source		Radiol Oncol
Vol. and No.		Letnik 40, št. 1
Publication year		2006
Volume		str. 39-42
Language		eng
Abstract		Background. Erlotinib is a novel biological anti-tumour agent in the treatment of advanced non small cell lung cancer. It represents the molecularly-targeted therapy which has been studied extensively. Case report. We present a case of a patient who suffered from advanced non-small-cell lung cancer. After the progress of disease following a prior chemotherapy he was treated with erlotinib with remarkable effect which was shown at chest x ray and symptoms were quite reduced. Conclusions. In selected patients with advanced non-small-cell lung cancer Erlotinib improves survival and symptom control as it results in presented case.
Summary		Izhodišča. Erlotinib je novo biološko protitumorsko zdravilo, ki ga uporabljamo pri bolnikih z nedrobnoceličnim rakom pljuč. Predstavlja molekularno tarčno terapijo, ki so jo zelo intenzivno proučevali v kliničnih študijah. Prikaz primera. Predstavljamo bolnika, ki smo ga obravnavali zaradi razširjene oblike nedrobnoceličnega raka pljuč. S kemoterapijo smo dosegli stagnacijo bolezni, ki je po desetih mesecih ponovno napredovala. Splošno stanje se je izrazito poslabšalo. Že po enem mesecu ponovnega sistemskega zdravljenja, tokrat z erlotinibom, so simptomi izzveneli in na rentgenski sliki prsnih organom vidimo znatno zmanjšanje bolezenskih sprememb (delno remisijo). Zaključki. Pri izbranih bolnikih z nedrobnoceličnim rakom pljuč lahko erlotinib podaljša preživetje in znatno zmanjša simptome bolezni.
Descriptors		LUNG NEOPLASMS CARCINOMA, NON-SMALL-CELL LUNG ANTINEOPLASTIC AGENTS RECEPTOR PROTEIN-TYROSINE KINASE MIDDLE AGE